Compare Flagstar Bank NA (FLG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Smith & Nephew plc — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while Smith & Nephew plc trades at $27.17 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.4× Flagstar Bank NA's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Smith & Nephew plc for 120 Days on average.
| FLG | SNN | |
|---|---|---|
Market Cap | $4.71B | $11.10B |
Volume | 7,410,589 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $15.36 | $37.17 |
52-Week Low | $10.72 | $26.42 |
Typical Hold Time | 21 Days | 120 Days |
Enterprise Value | $15.25B | $14.13B |
Dividend Yield | 0.35% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.30, down 2.25% on the day, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with Q2 2026 marking the third consecutive profitable quarter, though it missed EPS estimates. Analyst sentiment remains positive with a $17.07 consensus price target representing 51% upside potential. Recent strategic developments include a $250 million share repurchase program and a new core banking partnership with Fiserv.
The stock presents a compelling value opportunity trading at 0.62x book value, but faces risks from volatile earnings performance and negative cash flow trends. While analyst consensus is bullish with 60% buy ratings, investors should monitor execution on profitability improvements and the impact of recent strategic initiatives on long-term growth.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
